Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world Overall Survival in a large Italian cohort
Lung Cancer — Andreano A, Bergamaschi W, Russo AG, et al. | July 19, 2021
Researchers aimed at determining the average therapeutic effect of immune checkpoint inhibitors in any line of treatment in a 2016-2018 population-based cohort of patients with advanced non-small-cell lung cancer (NSCLC). From the cancer registry of the Agency for Health Protection of Milan, Italy, they derived cohort, and information on the tumor. They included 1,673 individuals, 324 of whom received anti PD-1/PD-L1 at any treatment line. Findings suggest correlation of treatment with anti PD–1/PD–L1 at any line with lowered hazard of death up to 2-years from date of diagnosis in this un-selected population-based cohort with advanced lung cancer. This supports the efficacy of immunotherapy outside clinical trials.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.